Skip to main content
TipRanks
Go Ultimate75% OFF

ReproCELL Inc. (4978) AI Stock Analysis

0 Followers
JP:4978

ReproCELL Inc.

(TSE/TYO:4978)

Select Model
Rating:43Neutral
Price Target:JPY 102.00â–¼(-2.86% Downside)
Action:reiterated
Date:09/10/26

The overall score of 43 reflects a high-risk investment profile heavily weighted by poor operational profitability and negative cash flows. The most significant risks are the severe operational losses and unprofitability, which drag down both the technical momentum and valuation metrics. However, the company's pristine, zero-debt balance sheet serves as a critical stabilizing factor, preventing immediate liquidity risks and keeping the score from hitting the absolute minimum.

Positive Factors
Debt-free balance sheetThe absence of meaningful debt reduces refinancing and interest burdens, giving ReproCELL greater flexibility through periods of weak earnings. This conservative funding structure also preserves room to support research, product development, and operating needs without relying heavily on creditors.
Negative Factors
Persistent cash burnPersistent negative free cash flow indicates that the business has not consistently funded its operations internally, even when accounting earnings improved. Continued cash burn can consume the company’s capital buffer and restrict its ability to invest, scale services, or withstand further operating weakness.

ReproCELL Inc. (4978) vs. iShares MSCI Japan ETF (EWJ)

-40%-30%-20%-10%0%10%20%30%40%JP:4978-34.78%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 11.10B
Dividend Yield
―
Average Volume (3M)
651.35K
Price to Earnings (P/E)
-23.7
Beta (1Y)
0.59
Revenue Growth
-8.23%
EPS Growth
-48.10%
Country
Japan
Employees
101
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ReproCELL Inc. Business Overview & Revenue Model

Company Description

Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, inc...

ReproCELL Inc. Financial Statement Overview

Summary

Despite an exceptionally strong, debt-free balance sheet that minimizes immediate financial risk, operational performance is highly vulnerable. Recent results show a swing to deep net losses, declining revenues, and substantial cash burn.

Income Statement

25Negative

Balance Sheet

92Very Positive

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.30B2.23B2.98B2.43B2.95B2.23B
Gross Profit1.06B1.01B1.63B1.10B1.13B785.42M
EBITDA-800.69M-785.10M-79.70M-372.18M-307.23M-587.37M
Net Income-436.88M-591.69M103.25M-31.41M-305.31M-575.10M
Balance Sheet
Total Assets9.80B9.65B9.67B9.05B8.36B8.10B
Cash, Cash Equivalents and Short-Term Investments5.62B6.51B3.94B6.57B6.38B4.64B
Total Debt0000080.00M
Total Liabilities727.77M805.59M685.81M741.03M780.63M844.53M
Stockholders Equity9.07B8.85B8.98B8.31B7.58B7.25B
Cash Flow
Free Cash Flow0-481.75M-80.40M-182.89M-290.92M-289.65M
Operating Cash Flow0-383.53M6.29M-11.45M-140.53M-246.24M
Investing Cash Flow057.94M-796.00M404.42M-1.09B-2.14B
Financing Cash Flow00680.11M544.05M482.87M2.38B

ReproCELL Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price105.00

Price Trends

50DMA128.40Negative
100DMA130.93Negative
200DMA146.64Negative

Market Momentum

MACD-6.06Positive
RSI33.28Neutral
STOCH24.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Negative. The current price of 105.00 is below the 20-day moving average (MA) of 116.40, below the 50-day MA of 128.40, and below the 200-day MA of 146.64, indicating a bearish trend. The MACD of -6.06 indicates Positive momentum. The RSI at 33.28 is Neutral, neither overbought nor oversold. The STOCH value of 24.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4978.

ReproCELL Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4978 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497843NeutralJPY 11.33B-23.68――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 25.58B-69.38――17.05%10.47%
JP:4599JP:459939UnderperformJPY 7.90B-4.21―――4.85%
JP:4593JP:459337UnderperformJPY 27.92B-12.37――-51.55%52.19%
JP:7776JP:777637UnderperformJPY 6.11B-4.70――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:4978JP:4593JP:4599JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4978 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4978ReproCELL Inc.105.00-55.00-34.38%
JP:4593Healios KK206.00-280.00-57.61%
JP:4599StemRIM Inc.126.00-151.00-54.51%
JP:7774Japan Tissue Engineering Co., Ltd.630.00151.0031.52%
JP:7776CellSeed Inc.154.00-225.00-59.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 10, 2026